Skip to main content
. 2014 Oct 30;9(11):1868–1875. doi: 10.2215/CJN.01080114

Table 3.

Association between MeDi score and upper quartile of eGFR decline

MeDi Score OR 
(95% CI) P 
Value
Continuous (per 1-point increase in MeDi score)
 Unadjusted 0.88 (0.80 to 0.96) 0.01
 Demographic adjusteda 0.89 (0.80 to 0.98) 0.02
 Fully adjustedb 0.88 (0.79 to 0.98) 0.02
MeDi score ≥5 (versus <5)
 Unadjusted 0.65 (0.48 to 0.88) 0.01
 Demographic adjusteda 0.65 (0.47 to 0.88) 0.01
 Fully adjustedb 0.58 (0.41 to 0.83) 0.003
MeDi quartiles (unadjusted)
 0–3 Ref
 4 0.81 (0.53 to 1.23) 0.32
 5 0.52 (0.33 to 0.82) 0.004
 6–9 0.63 (0.41 to 0.95) 0.03
MeDi quartiles (demographic adjusted)
 0–3 Ref
 4 0.86 (0.55 to 1.33) 0.49
 5 0.51 (0.32 to 0.81) 0.004
 6–9 0.66 (0.43 to 1.02) 0.06
MeDi quartiles (fully adjusted)
 0–3 Ref
 4 1.01 (0.62 to 1.66) 0.96
 5 0.49 (0.29 to 0.82) 0.01
 6–9 0.67 (0.41 to 1.10) 0.11
a

Adjusted for age (years), sex, race/ethnicity (black, white, Hispanic, or other), education (high school completion versus not), and insurance status (Medicare/private insurance versus Medicaid/no insurance).

b

Adjusted for age (years), sex, race/ethnicity (black, white, Hispanic, other), education (high school completion versus not), insurance status (Medicare/private insurance versus Medicaid/no insurance), physical activity (any exercise versus not), BMI (kg/m2), diabetes (yes or no), smoking status (never, past, or current), hypertension (yes or no), LDL (mg/dl), HDL (mg/dl), baseline eGFR (ml/min per 1.73 m2), and ACE inhibitor/ARB usage (yes or no).